I have found an article released two days ago about the research into a drug called TRC105 which is in development by a company called TRACON (San Diego, California) in collaboration with the National Cancer Institute in the USA.
"TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that the U.S Food and Drug Administration (FDA) has granted TRC105 orphan drug designation for the treatment of patients with soft tissue sarcoma."
I don't claim to be a science guru who entirely understands everything mentioned on the web page, but surely this is good news for future soft tissue Sarcoma patients? It seems to be in trial stages stages at the moment, but to me it seems that the company is quite optimistic.
“Orphan drug designation for TRC105 underscores the high level of unmet medical need in patients with soft tissue sarcomas and validates our commitment to developing TRC105 in a variety of orphan drug indications,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “We are highly encouraged by the clinical data reported to date from the Phase 1b/2 trial of TRC105 in sarcoma patients, especially in patients with angiosarcoma. We look forward to the availability of complete results from the Phase 2 portion of the sarcoma trial and initiating a pivotal Phase 3 trial in patients with angiosarcoma in 2016.”The evolution of the human brain is quite mind boggling. The advances we make as a human race are absolutely astonishing. The many people who put a lot of time and effort into working on cures, cures for any types of disease are nothing short of miracle workers.
I truly appreciate how lucky I am to have these people taking care of me.
LINK: pharmiweb.com TRC105 Soft Tissue Sarcoma
Brilliant the work they do, finding new treatments 👌
ReplyDelete